Corporate Updates 724

Dr Reddy’s CPS facility clears USFDA audit

Dr Reddy’s Laboratories has received establishment inspection report (EIR) from the US health regulator for a unit of its Srikakulam plant in Andhra Pradesh.

“The company has received EIR from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility at Srikakulam unit II,” Dr Reddy’s said in a filing to BSE.

The audit of the facility has been completed today with zero observations, the drug firm said.

The Custom Pharmaceutical Services (CPS) facility of Dr Reddy’s Laboratories Ltd at its Technology Development Centre (TDC-1), Miyapur has cleared the USFDA audit.

Most Popular

 

 


 

 

 

 

 

 

 

Get Heard Portal

 

eHealth Event Report

 

 

To Top